AstraZeneca is set to acquire FibroGen for $160 million to secure rights for the anemia treatment Roxadustat in China, enhancing their market presence in nephrology.
Target Information
On February 20, AstraZeneca announced an agreement to acquire FibroGen, Inc. (FGEN) for approximately $160 million (around 1.16 billion yuan) in a strategic move to gain ownership rights for the anemia treatment drug Roxadustat (brand name: Auryxia) in China. This transaction is expected to be finalized by mid-2025.
FibroGen primarily focuses on the biological research and innovative drug development involving connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF). The company celebrated a significant milestone in November 2014, successfully listing on NASDAQ, largely attributed to the promising candidate Roxadustat.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in China
The pharmaceutical industry in China has been undergoing rapid transformation, driven by reforms in healthcare and increased demand for innovative therapies. Th
Similar Deals
Hillhouse Investment Management → WuXi AppTec’s China-based clinical research services business
2025
Ascendent Capital Partners → Hollysys Automation Technologies Ltd.
2024
GL Capital Group → Huizhou Foryou Medical Devices Co., Ltd
2023
Hygeia Healthcare → Suzhou Yongding Hospital
2021
AstraZeneca
invested in
FiberGen
in 2025
in a Buyout deal
Disclosed details
Transaction Size: $160M